What is the recommended protocol for switching a patient from fluoxetine (Prozac) to atomoxetine, including tapering, washout period, and initial dosing?

Switching from Prozac (Fluoxetine) to Atomoxetine

Due to fluoxetine's extremely long half-life and its potent inhibition of CYP2D6 (the enzyme that metabolizes atomoxetine), you must start atomoxetine at half the usual dose and wait no specific washout period—fluoxetine can be stopped abruptly and atomoxetine started immediately, but the initial atomoxetine dose must be reduced to account for the drug interaction that will persist for weeks. 1

Key Pharmacological Consideration

The critical issue here is not the typical antidepressant switching concern, but rather a significant drug-drug interaction. Fluoxetine is a strong CYP2D6 inhibitor, and this inhibition persists for 4-6 weeks after discontinuation due to fluoxetine's active metabolite (norfluoxetine) having a half-life of 4-16 days 2. Atomoxetine is primarily metabolized via CYP2D6, so elevated atomoxetine levels will occur when these medications overlap or when atomoxetine is started soon after fluoxetine 2.

Recommended Protocol

Step 1: Discontinue Fluoxetine

• Fluoxetine can be stopped abruptly without tapering 1
• No washout period is required before starting atomoxetine
• The long half-life of fluoxetine (4-6 days) and norfluoxetine (4-16 days) provides a built-in taper effect

Step 2: Initiate Atomoxetine at Reduced Dose

For children/adolescents ≤70 kg:

• Start at 0.5 mg/kg/day (half the usual starting dose)
• Maintain this dose for 4 weeks while monitoring symptoms and tolerability
• Only increase to the target dose of 1.2 mg/kg/day if symptoms fail to improve AND the initial dose is well tolerated 1

For adolescents >70 kg and adults:

• Start at 40 mg/day (the usual starting dose, which is already conservative)
• Maintain for 4 weeks before considering increase
• Target dose is 80 mg/day, only increase if needed and tolerated 1

Step 3: Monitoring During Transition

Critical monitoring points:

• Cardiovascular parameters: Check heart rate and blood pressure at baseline and regularly during titration, as atomoxetine can increase both 3, 2
• Suicidality: Closely monitor for suicidal ideation, clinical worsening, and unusual behavioral changes, especially in the first few months (FDA black box warning for children/adolescents) 3, 2
• Gastrointestinal symptoms: Nausea, vomiting, and abdominal pain are common, particularly if dose escalation is too rapid 3, 2
• Somnolence and fatigue: Common initial side effects 2

Obtain cardiac history before starting:

• Personal history of cardiac symptoms
• Family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome
• Consider ECG if risk factors present 3

Important Caveats

Why This Approach Differs from Typical Antidepressant Switches

Unlike switching between antidepressants where washout periods may be needed to avoid serotonin syndrome, atomoxetine is not serotonergic—it's a norepinephrine reuptake inhibitor 2. The concern is purely pharmacokinetic (drug metabolism), not pharmacodynamic (receptor interactions).

The CYP2D6 Interaction Will Persist

Even after stopping fluoxetine, its inhibitory effect on CYP2D6 continues for 4-6 weeks. This means:

• Atomoxetine levels will remain elevated during this entire period
• The reduced starting dose accounts for this prolonged interaction
• Approximately 7% of patients are naturally poor CYP2D6 metabolizers and will have even higher atomoxetine levels 2

Timing of Full Therapeutic Effect

Atomoxetine requires 6-12 weeks to achieve full therapeutic effect 2, which is substantially longer than stimulants. Set appropriate expectations with patients and families that symptom improvement will be gradual, not immediate.

Screen for Bipolar Disorder

Before initiating atomoxetine, screen for personal or family history of bipolar disorder, mania, or hypomania 1. This is standard practice before starting any ADHD medication.

Alternative Consideration

If the patient was on fluoxetine for depression (not just as an incidental medication), recognize that atomoxetine is FDA-approved only for ADHD, not depression. If depressive symptoms are present, this switch may not address that indication. Consider whether the depression requires separate management or if ADHD treatment alone is the goal.